Sandoz Pushes Back On AMR And ‘Dysfunctional’ Antibiotics Market
Get Access Balance Right And Consider Market Reforms, Urge Senior Executives
Sandoz CEO Richard Saynor and global head of anti-infectives Ian Ball have spoken out on the threat of antimicrobial resistance and the “increasing dysfunctionality” of the market framework for antibiotics.
You may also be interested in...
Just weeks before Sandoz completes its separation from parent firm Novartis, the company has completed a deal for worldwide rights to the Mycamine antifungal brand from Astellas.
Sandoz has struck a deal with Adalvo that will give the company rights to six products in the US – four of which are potential first-to-market opportunities – targeting markets that are collectively worth around $3bn.
In the third and final part of his exclusive interview with Generics Bulletin, Sandoz CEO Richard Saynor discusses global off-patent industry challenges including antibiotics shortages, PBM behavior in the US and the UK’s VPAS rebate mechanism.